A US-based biopharmaceutical company, with immunology and immuno-oncology portfolio of monoclonal antibodies. Within their broad portfolio, the client was underway with their positive Phase 3 Clinical Trial (LIVE-AIR) for their drug, used to treat cytokine storm, in newly hospitalized COVID-19 patients. The client desired to quickly increase trial participants from 300 to 520.
Short time window to increase recruitment of patients for drug trial from 300 to 520
Promotion restrictions due to ongoing US election campaigns
Identifying relevant trial participants from the high volume of generic website traffic
Building credibility with patients and caregivers to participate in the trial
We augmented traditional CRO model with digital strategies, AI/ML applications, and medical data mining for precise and effective targeting. Engaging data-driven digital campaigns were deployed for diverse patient recruitment based on geography, demography and interest-based signals.
Hyperlocal campaigns in English and Spanish on search and social platforms with programmatic, lookalike, and re-targeting formats were activated for better reach and engagement among diverse patient and HCP pool. We used our in-house omnichannel CRM platform, built in partnership with Microsoft, for NPI-level HCP outreach geo-fenced within 50 miles of trial sites.
The client was able to achieve higher engagement and enrollments of patients for the trial owing to wider reach, precise targeting, and multi-lingual campaigns.
It received over 17,000 weekly unique visitors to trial landing page and qualified 7% patients through a primary screening process, resulting in 460 participants, qualified for secondary screening
Weekly unique visitors to trial landing page
Qualification rate through primary screening process
Participants qualified for secondary screening
Indegene has been a great partner in our clinical trial recruiting process for our drug to treat cytokine storms in hospitalized COVID-19 patients. They were able to go live quickly with their digital marketing campaign, helping us achieve the clinical trial size requirement within our timeline. They understood the specific challenges that we faced and utilized their IP to effectively target potential trial participants and qualifying them through a primary screening process.